Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Uterine Cervical Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumor 1Rectal Neoplasms 1Oligometastatic Prostate Cancer 1Neoplasms 1Metastatic Urothelial Cancer 1Lung Neoplasms 1Lung Diseases 1Locally Advanced Cervical Cancer 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1Erythrocytosis, Familial, 4 1Cholangiocarcinoma 1Carcinoid Tumor 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

pembrolizumab 55Carboplatin 33Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16130-nm albumin-bound paclitaxel 15Specimen Handling 14toripalimab 11Drug Therapy 11Magnetic Resonance Spectroscopy 10Biopsy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × zimberelimab × Clear all
NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Recruiting
31 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡